Assessment of serum vascular endothelial growth factor and nail fold capillaroscopy changes in systemic lupus erythematosus with and without cutaneous manifestations
Article first published online: 28 SEP 2011
© 2011 Japanese Dermatological Association
The Journal of Dermatology
Special Issue: Hair Biology and Hair Loss Disorders (pages 1-41)
Volume 39, Issue 1, pages 52–57, January 2012
How to Cite
MONEIB, H. A., SALEM, S. A. M., ALY, D. G., KHEDR, H. T. M., WAFAEY, H. A. and HASSAN, H. E. (2012), Assessment of serum vascular endothelial growth factor and nail fold capillaroscopy changes in systemic lupus erythematosus with and without cutaneous manifestations. The Journal of Dermatology, 39: 52–57. doi: 10.1111/j.1346-8138.2011.01322.x
- Issue published online: 29 DEC 2011
- Article first published online: 28 SEP 2011
- Received 24 February 2011; accepted 22 May 2011.
- nail fold capillaroscopy;
- cutaneous lupus erythematosus;
- systemic lupus erythematosus;
- vascular endothelial growth factor;
Angiogenesis and microvascular endothelial injury play a role in the pathogenesis of systemic lupus erythematosus (SLE). Vascular endothelial growth factor (VEGF), a key regulator of angiogenesis, and nail fold capillaroscopy (NFC) have been investigated in few studies in SLE with no reports targeting SLE with cutaneous manifestations. To evaluate NFC changes and VEGF serum level in relation to disease activity in SLE patients with versus without cutaneous manifestations. Thirty SLE patients (15 with cutaneous manifestations [group I], 15 without [group II]) and 15 healthy controls were evaluated for VEGF serum levels, NFC changes and were related to disease activity. VEGF serum levels were significantly higher in patients than controls (median and interquartile range [IQR]: 2110.77, 471.09–4714.30 vs 60.00, 14–366, respectively, P < 0.0001). VEGF cut-off value to predict SLE patients was more than 293 and to detect moderate and severe SLE activity was more than 422 pg/mL and more than 3800 pg/mL, respectively. Serum VEGF levels increased with increased disease activity (P < 0.05). It was significantly higher in group I than group II (median and IQR: 2624.74, 1801.39–4141.70 vs 862.50, 180–2426.95, respectively, P < 0.05). Mean serum VEGF was significantly higher with NFC score 3 than 1 (P = 0.008). NFC score and SLE activity were significantly associated in patients (P < 0.05). Serum VEGF is significantly elevated in SLE patients with cutaneous manifestations and its cut-off values to detect different activity grades of SLE are identified. Abnormalities in NFC reflect the extent of microvascular involvement in SLE.